3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Head & Neck
2
CNS
2
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
69
Carboplatin
66
Cisplatin
36
pembrolizumab
34
Gemcitabine
24
liposomal doxorubicin
23
Cyclophosphamide
23
Topotecan
22
Bevacizumab
20
Taxes
14
Docetaxel
13
niraparib
12
Nivolumab
12
olaparib
10
fludarabine
10
Doxorubicin
9
Surveys and Questionnaires
8
Radiotherapy
8
Oxaliplatin
8
aldesleukin
7
Filgrastim
7
rucaparib
6
oregovomab
6
fludarabine phosphate
6
durvalumab
6
avelumab
6
Interleukin-2
6
Hyperthermic Intraperitoneal Chemotherapy
6
Fluorodeoxyglucose F18
6
Cytoreduction Surgical Procedures
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
alectinib
×
Gynecologic
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts